Background and Purpose-We aimed to determine the association between stress hyperglycemia and risk of new stroke in patients with a minor ischemic stroke or transient ischemic attack. Methods-A subgroup of 3026 consecutive patients from 73 prespecified sites of the CHANCE trial (Clopidogrel in HighRisk Patients With Acute Nondisabling Cerebrovascular Events) were analyzed. Stress hyperglycemia was measured by glucose/glycated albumin (GA) ratio. Glucose/GA ratio was calculated by fasting plasma glucose divided by GA and categorized into 4 even groups according to the quartiles. The primary outcome was a new stroke (ischemic or hemorrhagic) at 90 days. We assessed the association between glucose/GA ratio and risk of stroke by multivariable Cox regression models adjusted for potential covariates. Results-Among 3026 patients included, a total of 299 (9.9%) new stroke occurred at 3 months. Compared with patients with the lowest quartile, patients with the highest quartile of glucose/GA ratio was associated with an increased risk of stroke at 3 months after adjusted for potential covariates (12.0% versus 9.2%; adjusted hazard ratio, 1.46; 95% confidence interval, 1.06-2.01). Similar results were observed after further adjusted for fasting plasma glucose. We also observed that higher level of glucose/GA ratio was associated with an increased risk of stroke with a threshold of 0.29 using a Cox regression model with restricted cubic spline. Conclusions-Stress hyperglycemia, measured by glucose/GA ratio, was associated with an increased risk of stroke in patients with a minor ischemic stroke or transient ischemic attack. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00979589.
S
tress hyperglycemia is the relative transient increase in glucose secondary to neurohormonal derangements and the inflammatory that occur during a critical illness like stroke. 1, 2 Previous study showed that acute stress hyperglycemia predicts increased risks of in-hospital mortality and poor functional recovery after ischemic stroke. 3 However, few study investigated the association of stress hyperglycemia with the risk of new stroke after ischemic stroke or transient ischemic attack (TIA). Furthermore, most previous studies defined stress hyperglycemia according to fasting or random glucose without considering the background glucose level, although they were analyzed by diabetic status. 3, 4 Previous study showed that relative hyperglycemia, defined as admission glucose divided by estimated average glucose derived from glycosylated hemoglobin (HbA1c), was a better predictive biomarker of critical illness than absolute hyperglycemia.
Glycated albumin (GA) is a well-validated measure of the mean glucose concentration over ≈2 to 4 weeks. 5, 6 GA can reflect the background glucose level before the event when tested within 2 days after the onset of stroke or TIA. In addition, GA is not affected by chronic kidney disease and anemia and can be more accurately reflecting the actual status of glycemic control compared with HbA1c. 7, 8 Therefore, it can be postulated that the ratio of fasting plasma glucose (FPG) to GA could reflect the stress hyperglycemia considering the background glucose level before the onset of event.
In this study, we investigated the association of stress hyperglycemia, measured by glucose/GA ratio, and outcomes of patients with a minor ischemic stroke or TIA, using the data derived from the CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events).
Methods

Study Participants
The CHANCE trial is a randomized, double-blind, controlled trial conducted at 114 hospitals in China between October 2009 and July 2012. Details on the rational, design, and major results of the CHANCE trial have been published previously. [9] [10] [11] In brief, 5170 patients with a minor ischemic stroke (National Institutes of Health Stroke Scale score of ≤3) or high-risk TIA (ABCD2 score [age, blood pressure, clinical features, duration of TIA, and diabetes] of ≥4) within 24 hours after onset of the events were randomized to the group of clopidogrel plus aspirin (day 1: clopidogrel 300 mg and open-label aspirin 75-300 mg; days 2-21: clopidogrel 75 mg and aspirin 75 mg/d; and days 22-90: clopidogrel 75 mg/d) or aspirin alone (day 1: open-label aspirin 75-300 mg; and days 2-90: aspirin 75 mg/d) in the CHANCE trial. The protocol of the CHANCE trial was approved by ethics committee at each study center. Written informed consent was obtained from all participants or their representatives before being enrolled into the study. Data are available to researchers on request for purposes of reproducing the results or replicating the procedure by directly contacting the corresponding author (yilong528@gmail.com).
Among 114 clinical sites included in the CHANCE trial, 73 (64%) sites with 3044 patients had prior experience collecting samples and agreed to participate in the prespecified biomarker substudy. All patients recruited by these 73 sites participated this substudy, and a separate written consent form was obtained from the patient.
Baseline Data Collection
Baseline data on demographics and cardiovascular risk factors were collected through face-to-face interviews by trained research coordinators from participating hospitals. Cardiovascular risk factors included history of ischemic stroke, TIA, myocardial infarction, angina, congestive heart failure, atrial fibrillation or flutter, valvular heart disease, hypertension, diabetes mellitus, hypercholesterolemia, and smoking status.
Assessment of Stress Hyperglycemia
Venous blood was drawn from patients after overnight fasting within the first 2 days after randomization. FPG was then measured. The serum specimens were collected and shipped on ice by overnight courier from each site to Beijing Tiantan Hospital, where all serum specimens were stored at −80°C. Serum GA levels were assayed with a kit (catalog number 4085-717; Ruiyuan Bio-Technique Co Ltd, Ningbo, China) using a Roche Modular P800 system in the clinical laboratory of Beijing Tiantan Hospital. 12 The GA level was expressed as a percentage of total serum albumin. All measurements were performed by laboratory personnel blinded to the study samples, study group assignments, and outcomes.
Stress hyperglycemia was measured by glucose/GA ratio, which was calculated using the following formula: glucose/GA ratio=FPG (mmol/L)/GA (%). The patients were then categorized into 4 groups by quartiles of glucose/GA ratio (Q1-Q4) for further comparisons. The novel index of glucose/GA ratio quantifies the extent of acute elevation in plasma glucose compared with the background plasma glucose levels.
Outcome Assessment
The primary outcome in the current analyses was a new stroke (ischemic or hemorrhagic) during the 90-day follow-up period, which was same as that in the trial. 10 Secondary outcomes included a new composite vascular event (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death) and ischemic stroke alone. All reported events were verified by a central adjudication committee that was blinded to the study group assignments.
Statistical Analysis
Continuous variables were presented as median with interquartile and categorical variables as percentages. The baseline characteristics of the patients included in and excluded from the analysis were compared using Wilcoxon rank-sum test for continuous variables and χ 2 test for categorical variables. The baseline variables among different quartiles of glucose/GA ratio were compared by Kruskal-Wallis test for continuous variables and χ 2 test for categorical variables. We tested the statistical significance of group of glucose/GA ratio×study group assignment in a multivariable Cox model to examine the interaction effect of category of stress hyperglycemia by study group assignment. Adjusted hazard ratios and their 95% confidence intervals were calculated using multivariable Cox regression models to assess the associations between quartiles of glucose/GA ratio and prognosis of minor stroke or TIA. In the multivariable regression analyses, 2 models were performed. In the first model, we adjusted for all the potential covariates including history of diabetes mellitus. In the second model, we further adjusted for FPG to assess the 
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independent association of stress hyperglycemia with the outcome controlled for absolute hyperglycemia. We further evaluated the pattern and magnitude of associations between glucose/GA ratio and risk of stroke using a Cox regression model with restricted cubic splines for glucose/GA ratio adjusting for covariates. The 25th percentile of the glucose/GA ratio (0.29) was treated as the reference, and the fifth, 25th, 50th, 75th, and 95th percentiles of glucose/GA ratio were treated as the 5 knots for spline.
All analyses were conducted with SAS 9.4 (SAS Institute Inc, Cary, NC), and a 2-sided P value <0.05 was considered to be statistically significant.
Results
Study Participants and Characteristics
A total of 3044 consecutive patients with a minor ischemic stroke or TIA were enrolled in the 73 sites for this substudy, among which 3026 (99.4%) patients had tested both FPG and GA. Table 1 shows the baseline characteristics of the patients included in this analysis. The patient included in and those excluded from this analysis were well balanced except that those included had a lower proportion of history of angina and diabetes mellitus, and TIA as the index event. Among the 3026 patients included, the median age was 62.2 (range, 37-94), and 1015 (33.5%) patients were female.
The median glucose/GA ratio was 0.33 (interquartile, 0.29-0.39). Table 2 shows the baseline characteristics of the patients by quartile of glucose/GA ratio. Patients with higher glucose/GA ratio were younger, less likely to be female and have a history of known atrial fibrillation or flutter, valvular heart disease, and diabetes mellitus, but more likely to be current smoker and have a history of hypercholesterolemia. Table 3 shows the 3-month prognosis after a minor stroke or TIA across quartiles of glucose/GA ratio. There were 299 (9.9%) new stroke occurrence at 3 months, among which 293 (98.0%) were ischemic stroke and 6 (2.0%) were hemorrhagic stroke. No interaction effect of study group assignment by categories of glucose/GA ratio was observed for the risk of stroke (P for interaction=0.41). Compared with patients with the lowest quartile, patients with the highest quartile of glucose/GA ratio had ≈1. Using a Cox regression model with restricted cubic spline, we found that higher level of glucose/GA ratio was associated with an increased risk of stroke with a threshold of 0.29 (Figure) .
Association of Stress Hyperglycemia With Outcome
Discussion
In this study, we found that the stress hyperglycemia on admission was associated with an increased risk of new stroke in patients with a minor ischemic stroke or TIA. This association was independent of absolute hyperglycemia on admission.
Table 3. Risk of Stroke at 3 Months After a Minor Stroke or Transient Ischemic Attack by Stress Hyperglycemia Status
Outcomes
Glucose/GA Ratio n Events, n (%) CI indicates confidence Interval; GA, glycated albumin; and HR, hazard ratio. *Model 1: adjusted for age, sex, history of ischemic stroke, transient ischemic attack, myocardial infarction, angina, congestive heart failure, known atrial fibrillation or flutter, valvular heart disease, hypertension, diabetes mellitus, hypercholesterolemia, smoking status, time to randomization, index event, and National Institutes of Health Stroke Scale on admission, antiplatelet therapy. †Model 2: adjusted for model 1+fasting plasma glucose. ‡Composite events: stroke, myocardial infarction, or death from cardiovascular causes.
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Stress hyperglycemia is common in patients with acute severe diseases, such as myocardial infarction and stroke. It was reported that the prevalence of stress hyperglycemia ranged from 8% to 63% in nondiabetic patients with acute stroke. 3 Differences in study population and definition of stress hyperglycemia may contribute to the heterogeneity of these estimates. Previous studies showed that acute stress hyperglycemia was associated with an increased risk of in-hospital mortality in diabetic and nondiabetic patients with myocardial infarction 13 and in-hospital mortality and poor functional recovery in nondiabetic patients with ischemic stroke. 3 Recent study also showed that hyperglycemia was associated with 3-month mortality in nondiabetic and good previous glucose controlled diabetic patients with acute ischemic stroke, but not in those with poor previous glucose controlled diabetics. 14 However, another study from Greece did not demonstrate significant direct association between stress hyperglycemia and outcome of acute ischemic stroke. 4 Previous studies mostly focused on the association of stress hyperglycemia and risk of mortality and poor functional outcome after stroke 3, 14 ; however, few study investigated the relationship between stress hyperglycemia and the risk of stroke recurrence. Our study further added the evidence that stress hyperglycemia was associated with an increased risk of new stroke in patients with acute ischemic stroke or TIA.
Although the mechanism is not fully understood, several explanations may account for the observed association between stress hyperglycemia and an increased risk of new stroke after minor stroke or TIA. First, higher relative rises of glycemia represent a greater inflammatory and neurohormonal response to the acute events and release of inflammatory and vasoconstrictive factors.
2 Second, glucose fluctuations may aggravate endothelial dysfunction and oxidative stress, which are 2 key players in favoring cardiovascular and cerebrovascular events. 15, 16 Third, hyperglycemia may also induce platelet aggregation. Previous study showed that hyperglycemia has a deleterious effect on platelet function. 17 These pathological changes tend to promote atherosclerosis and subsequent stroke.
Stress hyperglycemia was usually diagnosed according to absolute hyperglycemia without previous diabetes mellitus or preexisting diabetes mellitus with deterioration of premorbid glycemic control. 1, 3 However, this definition failed to distinguish stress hyperglycemia from newly diagnosed diabetes mellitus or unknown diabetes mellitus and did not consider the background glucose level. In contrast, relative measures of hyperglycemia, such as glucose/GA ratio, represent a quantitative measurement of the relative acute rises in plasma glucose concentration compared with premorbid glucose status. Previous study showed that relative measures controlling for background glycemia were a better biomarker of critical illness than absolute hyperglycemia. 2 Furthermore, GA level reflects mean glycemia over ≈2 to 4 weeks. Measures of stress hyperglycemia based on GA are not affected by chronic kidney disease, anemia, or hemoglobinopathies, 7, 8 unlike those measures based on HbA1c, such as the stress hyperglycemia ratio (defined as admission glucose divided by estimated average glucose derived from HbA1c) 2 and plasma glucose concentration/HbA1c ratio 18 used in the previous studies. It was reported that >40% of stroke patients had reduced estimated glomerular filtration rate. 19 In addition, a separate specimen of whole blood is required to measure HbA1c, but GA can be measured from serum or plasma with the blood glucose level. 12 On the other hand, measurement of GA was affected by alteration in serum albumin metabolism. In addition, there is no consistent agreement of cutoff levels of GA suggesting that diabetes mellitus is present. 7 Results from the Kyushu and Okinawa Population Study showed that FPG concentrations of 5.56, 6.11, and 7.00 mmol/L corresponded to HbA1c levels of 5.6%, 5.9%,and 6.3% and GA levels of 15.0%, 15.7%, and 16.9%, respectively. 5 Nevertheless, our study has suggested a practical and economical method to precisely detect and quantify stress hyperglycemia, which provides prognostic information in patients with acute minor ischemic stroke or TIA.
This study has several limitations. First, we could not estimate the association between stress hyperglycemia and stroke prognosis by stroke cause because the baseline data of cause classification for enrolled patients were not collected in the CHANCE trial. Second, only Chinese patients were enrolled in the trial. Chinese patients with ischemic stroke or TIA had a higher prevalence of large artery atherosclerosis. 20, 21 This limits the generalizability of the findings to a Western population with a different disease pattern of ischemic stroke.
Conclusions
Our results demonstrated that stress hyperglycemia, measured by glucose/GA ratio, was associated with an increased risk of new stroke in patients with a minor ischemic stroke or TIA. 
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